These disclosures are from 13Ds filed with the Securities and Exchange Commission. 13Ds are filed within 10 days of an entity's attaining more than 5% in any class of a company's securities. Subsequent changes in holdings or intentions must be reported in amended filings. This material is from Aug. 13 through Aug. 19, 2026. Source: VerityData
Increases in Holdings
Exelixis $(EXEL)$ Farallon Capital Management raised its stake in the oncology-focused biotechnology company to 13,989,010 shares. Farallon Capital Management did so through the purchase of 1,221,000 Exelixis shares from June 18 through Aug. 10 at per share prices ranging from $51.37 to $56.92, and partially offset those purchases through the sale of 507,000 shares from June 18 through July 17 at $51.34 to $55.77. Following the latest activity, Farallon Capital Management continues to own a 5.6% stake in Exelixis' outstanding stock. Shares of Exelixis have gained about 24.6% in value in 2026.
Decreases in Holdings
Valaris $(VAL)$ Oak Hill Advisors lowered its stake in the offshore drilling company to 3,038,600 shares. Oak Hill Advisors did so through the sale of 884,020 Valaris shares from June 15 through Aug. 12 at per share prices ranging from $80.01 to $87.36. Following the latest sales, Oak Hill Advisors owns a 4.4% stake in Valaris' outstanding stock, placing Oak Hill below the 5% threshold that would require it to report further sales. Shares of Valaris have gained roughly 66.5% in value in 2026.
Allient $(ALNT)$ Juniper Investment lowered its stake in the motion control products maker to 596,314 shares. Juniper Investment did so through the sale of 165,991 Allient shares from Aug. 11 through Aug. 13 at per share prices ranging from $109.08 to $118.50. Following the latest sales, Juniper Investment continues to own a 3.5% stake in Allient's outstanding stock, placing Juniper below the 5% threshold that would require it to report further sales. Shares of Allient have gained roughly 84.5% in value in 2026.
BridgeBio Pharma (BBIO) KKR Genetic Disorder lowered its stake in the genetic disease-focused biopharmaceutical company to 9,232,739 shares. KKR Genetic Disorder did so through the sale of five million BridgeBio Pharma shares on Aug. 13 at a price of $77.42 per share pursuant to an underwritten secondary offering. Following the latest sale, KKR Genetic Disorder continues to own a 4.7% stake in BridgeBio Pharma's outstanding stock, placing KKR below the 5% threshold that would require it to report further sales. Shares of BridgeBio Pharma have gained about 7.2% in value in 2026.
Life Time Group Holdings (LTH) Leonard Green & Partners lowered its stake in the fitness club operator to 5,908,604 shares. Leonard Green & Partners did so through the sale of 5,119,099 Life Time shares into a secondary offering on Aug. 10 at a price of $43.16 per share. Following the latest sale, Leonard Green & Partners continues to own a 2.6% stake in Life Time Group Holdings' outstanding stock, placing Leonard Green below the 5% threshold that would require it to report further sales. Shares of Life Time Group Holdings have gained about 68.1% in value in 2026.
Email: editors@barrons.com